Claims

1. Use of a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor in the manufacture of a medicament for ~~preventing or~~ treating cystic fibrosis by improving conductance of chloride by cystic fibrosis transmembrane conductance regulator (CFTR).

2. The use according to claim 1 wherein said prostacyclin analogue is selected from the group of Treprostinil, Iloprost, Cicaprost or Beraprost or pharmaceutically acceptable salts thereof.

3. The use according to any one of claim 1 or 2, wherein said prostacyclin analogue is selected from the group of acid derivatives of Treprostinil, prodrugs of Treprostinil, polymorphs of Treprostinil or isomers of Treprostinil.

4. The use according to any one of claims 1 to 3, wherein said PDE4 inhibitor is selected from the group of Ro 20-1724, Ibudilast, Roflumilast and its N-Oxide, Cilomilast, BAY 19-8004, CC3, AWD 12-281, SCH 351591, Ciclamilast, Piclamilast, CGH2466, Mesembrine, Rolipram, Luteolin and Drotaverine.

5. Composition comprising Treprostinil and a PDE4 inhibitor selected from the group of RO 20-1724, Roflumilast and Ibudilast.

6. The use according to any one of claims 1 to 4, or composition according to claim 5, wherein a further PDE inhibitor selected from the group of PDE5, PDE7 or PDE8 inhibitors is contained.

7. The use or composition according to claim 6, wherein said PDE5 inhibitor is selected from Avanafil, Lodenafil, Mirodenafil, Sildenafil citrate, Tadalafil, Vardenafil or Udenafil.

8. The use or composition according to claim 6, wherein said PDE7 and PDE8 inhibitors are selected from Dipyridamol, BRL50481 and PF-4957325.

9. The use or composition according to any one of claims 1 to 8, wherein the medicament is a pharmaceutical composition.

10. The use or composition according to any one of claims 1 to 9 for inhalation.

11. The use or composition according to any one of claims 1 to 9 for intravenous or subcutaneous administration, or orally available form selected from the group of sustained release forms, tablets and capsules.

12. The use according to any one of claims 1 to 11 wherein the effective amount of Treprostinil or a pharmaceutically acceptable salt thereof is at least 1.0 ng/kg of body weight.

~~13. Method for increasing the cAMP level in a cell in vitro wherein said cell is contacted with at least one prostacyclin or prostacyclin analogue and at least one~~

~~PDE4 inhibitor and optionally at least one inhibitor selected from the group of or PDE5 inhibitors, PDE7 inhibitors or PDE8 inhibitors or a pharmaceutically acceptable salt thereof.~~

13~~14~~. A therapeutic combination, comprising at least one prostacyclin or prostacyclin analogue and at least one PDE4 inhibitor and at least one inhibitor selected from the group of or PDE5 inhibitors, PDE7 inhibitors or PDE8 inhibitors , wherein the prostacyclin or prostacyclin analogue and PDE4 inhibitor and at least one inhibitor selected from the group of PDE5 inhibitors, PDE7 inhibitors and PDE8 inhibitors are provided in amounts which together are sufficient to treat and/or prevent at least one symptom associated with cystic fibrosis.

14~~15~~. Therapeutic combination according to claim ~~14~~13, wherein the prostacyclin or prostacyclin analogue and PDE4 inhibitor and at least one inhibitor selected from the group of PDE5 inhibitors, PDE7 inhibitors and PDE8 inhibitors are formulated for administration by inhalation.